Florian Kuchenbauer

As a researcher, Dr. Florian Kuchenbauer has been working on acute myeloid leukemia (AML) and normal hematopoiesis with a focus on non-coding RNAs for the past 17 years. His work has significantly contributed to the field. Collaborating closely with many top researchers in the field, we were the first to apply next-generation sequencing of miRNAs in AML cells. We also created the first detailed miRNA expression atlas for normal hematopoiesis and participated in explored the role of miRNAs in the 5q-Syndrome. My group at Ulm University developed the first in vivo leukemia progression model based on miRNA overexpression and defined the miR-193 family as novel strong tumor suppressor miRNAs in AML. At BC Cancer, we are working on novel lipid nanoparticle based drug formulations for AML patients. We are also exploring metabolic vulnerabilities of high-risk AML, a patient group that is currently therapeutically underserved. In addition, we are working on multiple myeloma, an incurable disease.

As a clinician, I worked in the Bone Marrow Transplant unit at Ulm University Hospital as a group leader from 2012 to 2018. My team analyzed the transplantation outcome of AML patients undergoing allogenic stem cell transplantation. I further contributed to the identification of the Graft vs Leukemia effect in FLT3 mutated AML and the role of clonal hematopoiesis in stem cell donors. Taken together, I aim to find translational solutions for patients based on “real-life” clinical problems.

For an up-to-date list of publications by Dr. Kuchenbauer, visit ORCID.